Special Issue "Exploiting Viruses to Attack Cancer Cells"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Animal Viruses".

Deadline for manuscript submissions: closed (30 September 2021).

Special Issue Editor

Dr. Fumihiro Higashino
E-Mail Website
Guest Editor
1. Department of Molecular Oncology, Hokkaido University Faculty of Dental Medicine and Graduate School of Biomedical Science and Engineering;
2. Department of Vascular Biology and Molecular Pathology, Hokkaido University Faculty of Dental Medicine and Graduate School of Dental Medicine, Sapporo, Japan
Interests: Adenovirus; oncolytic adenovirus; AU-rich elment; HuR; E4orf6; E1A; ARE-mRNA; export; stabilization

Special Issue Information

Dear colleagues,

Oncolytic virus (OV) is a promising therapeutic approach for the treatment of cancer that utilizes the replication of the virus in a tumor cell-specific manner. Advanced genetic engineering techniques have made it possible to modify these viruses, resulting in targeted destruction of not only tumor cells, but also the ability of the host to stimulate the anti-tumor immune response. Many viral species, such as Herpesvirus, Vaccinia virus, Measles virus, Newcastle virus, and Adenovirus, were designed or modified as oncolytic viruses. And many types of genetically engineered OV have been examined in detail, as, for example, the viruses which have mutations in the genes required for viral replication. The other type consists of viruses which possess a cancer-specific transcription system in the virus genes required for replication. Recently, viruses that can activate antigen-presenting cells such as dendritic cells and can induce tumor immunity are becoming mainstream.

The purpose of this Special Issue of Viruses is to give an overview of the challenges faced by OV-based cancer treatments and various efforts to improve their therapeutic effects, including activation of tumor immunity.

Dr. Fumihiro Higashino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • oncolytic virus
  • gene therapy
  • cancer
  • tumor immunity
  • immunotherapy
  • genetic engineering
  • viral replication

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop